UB Paderborn / Katalog / Suche / in CDI

Tadalafil Therapy for Pulmonary Arterial Hypertension

Circulation (New York, N.Y.), 2009-06, Vol.119 (22), p.2894-2903

2009

Volltextzugriff (PDF)

Diagnosis and Assessment of Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2009-06, Vol.54 (1), p.S55-S66

2009

Volltextzugriff (PDF)

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2009-11, Vol.54 (21), p.1971-1981

2009

Volltextzugriff (PDF)

Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension

Chest, 2013-02, Vol.143 (2), p.315-323

2013

Volltextzugriff (PDF)

End Points and Clinical Trial Design in Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2009-06, Vol.54 (1), p.S97-S107

2009

Volltextzugriff (PDF)

Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2006-12, Vol.174 (11), p.1257-1263

2006

Volltextzugriff (PDF)

Pulmonary hypertension associated with left-sided heart disease

Clinics in chest medicine, 2007-03, Vol.28 (1), p.233

Oudiz, Ronald J

2007

Volltextzugriff (PDF)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary circulation, 2020-04, Vol.10 (2), p.1-7

2020

Volltextzugriff (PDF)

Classification of Pulmonary Hypertension

Cardiology clinics, 2016-08, Vol.34 (3), p.359

Oudiz, Ronald J

2016

Volltextzugriff (PDF)

End-tidal Pco2 Abnormality and Exercise Limitation in Patients With Primary Pulmonary Hypertension

Chest, 2005-05, Vol.127 (5), p.1637-1646

2005

Volltextzugriff (PDF)

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

Chest, 2009-01, Vol.135 (1), p.122-129

2009

Volltextzugriff (PDF)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

Respiratory research, 2019-09, Vol.20 (1), p.208-208, Article 208

2019

Volltextzugriff (PDF)

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

The Journal of heart and lung transplantation, 2011-06, Vol.30 (6), p.632-643

2011

Volltextzugriff (PDF)

Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension

The American journal of cardiology, 2011-07, Vol.108 (2), p.302-307

2011

Volltextzugriff (PDF)

Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing

PloS one, 2010-12, Vol.5 (12), p.e14293-e14293

2010

Volltextzugriff (PDF)

Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Chest, 2004-08, Vol.126 (2), p.420-427

2004

Volltextzugriff (PDF)

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

The New England journal of medicine, 2015-08, Vol.373 (9), p.834-844

2015

Volltextzugriff (PDF)

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)

Respiratory medicine, 2017-05, Vol.126, p.84-92

2017

Volltextzugriff (PDF)

Pulmonary Hypertension

Cardiology clinics, 2016-08, Vol.34 (3), p.ix

Oudiz, Ronald J

2016

Volltextzugriff (PDF)

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D22-D33

2013

Volltextzugriff (PDF)

Cardiopulmonary Exercise Testing and Six-Minute Walk Correlations in Pulmonary Arterial Hypertension

The American journal of cardiology, 2006, Vol.97 (1), p.123-126

2006

Volltextzugriff (PDF)

Usefulness of Right-to-Left Shunting and Poor Exercise Gas Exchange for Predicting Prognosis in Patients With Pulmonary Arterial Hypertension

The American journal of cardiology, 2010-04, Vol.105 (8), p.1186-1191

2010

Volltextzugriff (PDF)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil

Pulmonary circulation, 2023-07, Vol.13 (3), p.e12255-e12255

2023

Volltextzugriff (PDF)

Pulmonary function in primary pulmonary hypertension

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.1028-1035

2003

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Tadalafil Therapy for Pulmonary Arterial Hypertension

Diagnosis and Assessment of Pulmonary Arterial Hypertension

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension

End Points and Clinical Trial Design in Pulmonary Arterial Hypertension

Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension

Pulmonary hypertension associated with left-sided heart disease

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Classification of Pulmonary Hypertension

End-tidal Pco2 Abnormality and Exercise Limitation in Patients With Primary Pulmonary Hypertension

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study

Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension

Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing

Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)

Pulmonary Hypertension

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Cardiopulmonary Exercise Testing and Six-Minute Walk Correlations in Pulmonary Arterial Hypertension

Usefulness of Right-to-Left Shunting and Poor Exercise Gas Exchange for Predicting Prognosis in Patients With Pulmonary Arterial Hypertension

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil

Pulmonary function in primary pulmonary hypertension

Suchergebnisse filtern